Reuters logo
Lonza to replace Actelion in Swiss blue-chip index -stock exchange
2017年4月24日 / 下午3点55分 / 7 个月前

Lonza to replace Actelion in Swiss blue-chip index -stock exchange

ZURICH, April 24 (Reuters) - Drug ingredients maker Lonza will replace biotech company Actelion in Switzerland’s blue-chip SMI stock index, the Swiss stock exchange said on Monday.

The change will take effect on May 3, Switzerland’s SIX exchange said in a statement.

U.S. healthcare giant Johnson & Johnson is buying Actelion in a $30 billion all-cash deal. Analysts had considered Lonza the favourite to replace Actelion ahead of the likes of construction chemicals specialist Sika and hearing aid maker Sonova. (Reporting by Joshua Franklin; Editing by Adrian Croft)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below